CN103597072B - 单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法 - Google Patents
单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法 Download PDFInfo
- Publication number
- CN103597072B CN103597072B CN201380001273.1A CN201380001273A CN103597072B CN 103597072 B CN103597072 B CN 103597072B CN 201380001273 A CN201380001273 A CN 201380001273A CN 103597072 B CN103597072 B CN 103597072B
- Authority
- CN
- China
- Prior art keywords
- monocyte
- manufacturing
- dendritic cells
- cell
- dendritic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001616 monocyte Anatomy 0.000 title claims abstract description 221
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 102
- 230000004663 cell proliferation Effects 0.000 title claims abstract description 69
- 210000005087 mononuclear cell Anatomy 0.000 title claims abstract description 69
- 239000001963 growth medium Substances 0.000 title claims abstract description 59
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 79
- 229940029030 dendritic cell vaccine Drugs 0.000 title claims description 39
- 230000004069 differentiation Effects 0.000 claims abstract description 42
- 108010002386 Interleukin-3 Proteins 0.000 claims abstract description 21
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 18
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 18
- 238000012545 processing Methods 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 82
- 238000000034 method Methods 0.000 claims description 37
- 239000002994 raw material Substances 0.000 claims description 24
- 210000001124 body fluid Anatomy 0.000 claims description 23
- 239000010839 body fluid Substances 0.000 claims description 23
- 239000011324 bead Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 238000003860 storage Methods 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 12
- 210000005259 peripheral blood Anatomy 0.000 claims description 12
- 239000011886 peripheral blood Substances 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 210000003743 erythrocyte Anatomy 0.000 claims description 7
- 210000000265 leukocyte Anatomy 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract description 13
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 230000035755 proliferation Effects 0.000 description 20
- 102000000646 Interleukin-3 Human genes 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 10
- 238000000926 separation method Methods 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 7
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102100035793 CD83 antigen Human genes 0.000 description 4
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 4
- 239000002458 cell surface marker Substances 0.000 description 4
- 238000000432 density-gradient centrifugation Methods 0.000 description 4
- 238000007898 magnetic cell sorting Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- 101710177504 Kit ligand Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
总细胞数(×107) | 活细胞率 | |
患者1 | 1.05 | 97.2% |
患者2 | 1.09 | 96.5% |
患者3 | 1.10 | 97.0% |
患者4 | 1.15 | 97.0% |
患者5 | 1.03 | 97.0% |
患者6 | 1.01 | 97.3% |
患者7 | 1.03 | 98.1% |
患者8 | 1.04 | 97.3% |
患者9 | 1.23 | 97.5% |
患者10 | 1.04 | 97.7% |
患者11 | 1.06 | 97.9% |
患者12 | 1.17 | 96.7% |
患者13 | 1.10 | 98.7% |
患者14 | 1.14 | 97.8% |
患者15 | 1.07 | 97.1% |
患者16 | 1.12 | 97.1% |
患者17 | 1.03 | 97.9% |
患者18 | 1.05 | 98.2% |
患者19 | 1.11 | 96.7% |
患者20 | 1.02 | 97.8% |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811217345.7A CN109536446B (zh) | 2012-02-10 | 2013-02-08 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012027332 | 2012-02-10 | ||
JP2012-027332 | 2012-02-10 | ||
PCT/JP2013/053154 WO2013118899A1 (ja) | 2012-02-10 | 2013-02-08 | 単球増殖剤、単球増殖用培地、単球の製造方法、樹状細胞の製造方法、及び樹状細胞ワクチンの製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811217345.7A Division CN109536446B (zh) | 2012-02-10 | 2013-02-08 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103597072A CN103597072A (zh) | 2014-02-19 |
CN103597072B true CN103597072B (zh) | 2018-11-23 |
Family
ID=48947651
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380001273.1A Active CN103597072B (zh) | 2012-02-10 | 2013-02-08 | 单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法 |
CN201811217345.7A Active CN109536446B (zh) | 2012-02-10 | 2013-02-08 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811217345.7A Active CN109536446B (zh) | 2012-02-10 | 2013-02-08 | 单核细胞增殖剂、单核细胞增殖用培养基、及单核细胞的制造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9303247B2 (zh) |
EP (1) | EP2749639B1 (zh) |
JP (1) | JP5577472B2 (zh) |
KR (1) | KR101680164B1 (zh) |
CN (2) | CN103597072B (zh) |
DE (1) | DE13746292T1 (zh) |
SG (1) | SG11201404570WA (zh) |
TW (1) | TWI607017B (zh) |
WO (1) | WO2013118899A1 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013169060A1 (ko) | 2012-05-11 | 2013-11-14 | 주식회사 카엘젬백스 | 패혈증 예방 또는 치료용 조성물 |
CN108949717B (zh) | 2012-05-11 | 2023-06-20 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
ES2716870T3 (es) | 2013-04-19 | 2019-06-17 | Gemvax & Kael Co Ltd | Composición para el tratamiento y prevención de lesión isquémica |
CA2912557A1 (en) | 2013-06-07 | 2014-12-11 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
KR102166545B1 (ko) | 2013-06-21 | 2020-10-16 | 주식회사 젬백스앤카엘 | 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법 |
KR102494803B1 (ko) | 2013-11-22 | 2023-02-06 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
ES2809251T3 (es) | 2013-12-17 | 2021-03-03 | Gemvax & Kael Co Ltd | Composición para tratar cáncer de próstata |
CN106456697B (zh) | 2014-04-11 | 2019-12-17 | 珍白斯凯尔有限公司 | 具有纤维化抑制活性的肽和含有其的组合物 |
ES2962532T3 (es) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante |
KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
EP3263122B1 (en) | 2015-02-27 | 2020-05-06 | Gemvax & Kael Co., Ltd. | Peptide for preventing hearing loss, and composition comprising same |
US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
JP6903866B2 (ja) * | 2016-01-27 | 2021-07-14 | 国立大学法人 熊本大学 | 血液由来単球の増殖誘導方法 |
EP3441082B1 (en) | 2016-04-07 | 2023-06-21 | Gemvax & Kael Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
EP3468581A1 (en) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
JP7146732B2 (ja) * | 2016-07-13 | 2022-10-04 | オハイオ ステート イノベーション ファウンデーション | 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法 |
US20180161546A1 (en) * | 2016-12-12 | 2018-06-14 | National Guard Health Affairs | Intravenous catheter stopper |
CN111432836A (zh) | 2017-09-05 | 2020-07-17 | 转矩医疗股份有限公司 | 治疗性蛋白质组合物及其制备和使用方法 |
CN108398470B (zh) * | 2018-04-13 | 2024-01-30 | 广州万孚生物技术股份有限公司 | 血液活化凝血时间测定生物传感器及其制作方法 |
AR118859A1 (es) * | 2019-05-08 | 2021-11-03 | Neon Therapeutics Inc | Composiciones y métodos de fabricación de células t |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101612402A (zh) * | 2001-01-09 | 2009-12-30 | 贝勒研究院 | 干扰素拮抗剂和Flt3L拮抗剂的用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0633929B1 (en) * | 1992-04-01 | 2004-03-03 | The Rockefeller University | METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS |
US6017527A (en) * | 1996-07-10 | 2000-01-25 | Immunex Corporation | Activated dendritic cells and methods for their activation |
AU7499498A (en) * | 1997-05-21 | 1998-12-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods and compositions for making dendritic cells from expanded populations ofmonocytes and for activating t cells |
CN101070540B (zh) * | 2000-04-28 | 2015-04-01 | 约翰霍普金斯大学 | 新的树突状细胞共刺激分子 |
GB0017990D0 (en) * | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
EP1350262B8 (en) * | 2000-12-08 | 2008-08-13 | Coley Pharmaceuticals GmbH | Cpg-like nucleic acids and methods of use thereof |
TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
AU2002951082A0 (en) * | 2002-08-30 | 2002-09-12 | The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland | Therapeutic cellular agents |
AU2004214896A1 (en) | 2003-02-27 | 2004-09-10 | Northwest Biotherapeutics, Inc. | Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines |
ES2553133T3 (es) * | 2004-06-04 | 2015-12-04 | Cel-Sci Corporation | Método de modificación de la proporción de CD4/CD8 y del infiltrado celular mononuclear en un tumor |
US8513008B2 (en) * | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
KR20150032915A (ko) * | 2005-04-08 | 2015-03-30 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
US7553661B2 (en) * | 2005-05-31 | 2009-06-30 | Mcgill University | Stromal antigen-presenting cells and use thereof |
EP1944361A1 (en) | 2007-01-11 | 2008-07-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for expanding monocytes |
KR20100031503A (ko) * | 2007-05-16 | 2010-03-22 | 판제네틱스 비.브이. | 조혈 전구 세포의 분화를 향상시키는 수단 및 방법 |
KR101661365B1 (ko) * | 2008-03-28 | 2016-09-29 | 모모타로겐 가부시키가이샤 | 단구로부터 수상 세포양 분화를 유도하여, 항암 면역 활성을 높이는 암의 치료 또는 예방을 위한 의약 조성물 |
-
2013
- 2013-02-08 DE DE13746292.5T patent/DE13746292T1/de active Pending
- 2013-02-08 JP JP2013541894A patent/JP5577472B2/ja active Active
- 2013-02-08 WO PCT/JP2013/053154 patent/WO2013118899A1/ja active Application Filing
- 2013-02-08 KR KR1020147025202A patent/KR101680164B1/ko active IP Right Grant
- 2013-02-08 CN CN201380001273.1A patent/CN103597072B/zh active Active
- 2013-02-08 EP EP13746292.5A patent/EP2749639B1/en active Active
- 2013-02-08 US US14/343,240 patent/US9303247B2/en active Active
- 2013-02-08 SG SG11201404570WA patent/SG11201404570WA/en unknown
- 2013-02-08 CN CN201811217345.7A patent/CN109536446B/zh active Active
- 2013-02-18 TW TW102105556A patent/TWI607017B/zh active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101612402A (zh) * | 2001-01-09 | 2009-12-30 | 贝勒研究院 | 干扰素拮抗剂和Flt3L拮抗剂的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109536446A (zh) | 2019-03-29 |
JPWO2013118899A1 (ja) | 2015-05-11 |
KR101680164B1 (ko) | 2016-11-28 |
CN103597072A (zh) | 2014-02-19 |
KR20140144681A (ko) | 2014-12-19 |
JP5577472B2 (ja) | 2014-08-20 |
EP2749639A1 (en) | 2014-07-02 |
EP2749639A4 (en) | 2015-01-21 |
US9303247B2 (en) | 2016-04-05 |
WO2013118899A1 (ja) | 2013-08-15 |
US20150030634A1 (en) | 2015-01-29 |
DE13746292T1 (de) | 2014-10-30 |
CN109536446B (zh) | 2022-08-02 |
TWI607017B (zh) | 2017-12-01 |
SG11201404570WA (en) | 2014-11-27 |
TW201341400A (zh) | 2013-10-16 |
EP2749639B1 (en) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103597072B (zh) | 单核细胞增殖剂、单核细胞增殖用培养基、单核细胞的制造方法、树突状细胞的制造方法、及树突状细胞疫苗的制造方法 | |
JP2021045176A (ja) | 未成熟な単球性樹状細胞の活性化を誘導するための組成物および方法 | |
JP2007536936A (ja) | 幹細胞集団および使用方法 | |
JP2002515756A (ja) | 選択されたリンパ球の生産方法 | |
JP2009518045A5 (zh) | ||
CN101490246A (zh) | 自吸脂后脂肪吸取物分离及纯化造血干细胞 | |
KR20080015033A (ko) | 배아 줄기 세포로부터 가지 세포를 형성하는 방법 | |
CA3048831C (en) | Method for obtaining monocytes or nk cells | |
CN109496236A (zh) | 改变的粘附基质细胞及其产生和使用方法 | |
CN102154208A (zh) | Cd133+脑胶质瘤干细胞抗原负载树突状细胞的制法及其应用 | |
US20150353897A1 (en) | Method of generating multilineage potential cells | |
CN107641617B (zh) | 体外高效制备非人灵长类动物巨核细胞及血小板的体系及其应用 | |
JP2005527223A (ja) | サイトカインフリーでの前駆細胞の増殖および維持 | |
Kim et al. | IL-22 producing NKp46+ innate lymphoid cells can differentiate from hematopoietic precursor cells | |
AU2013206016B2 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1194101 Country of ref document: HK |
|
CB02 | Change of applicant information |
Address after: Tokyo, Japan, Japan Applicant after: HAKUSHINKOUSEIKAI FOUNDATION Applicant after: Immunology genetics Corporation Address before: Tokyo, Japan, Japan Applicant before: HAKUSHINKOUSEIKAI FOUNDATION Applicant before: LIFE SCIENCE RESEARCH INSTITUTE LTD. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |